Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
LEXINGTON, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that Keros' Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will present at the following healthcare conferences:
Keros Therapeutics, Inc.（以下簡稱"Keros"或"公司"）（納斯達克：KROS）是一家臨床階段的生物製藥公司，致力於開發和商業化與變形生長因子-β（"TGF-ß"）蛋白家族信號功能異常相關的多種疾病患者的新型治療藥物。今天，Keros的主席兼首席執行官Jasbir S. Seehra博士將在以下醫療健康學術會議上進行演講：
Morgan Stanley 22nd Annual Global Healthcare Conference
摩根士丹利第22屆全球醫療保健大會
- Date and Time: Wednesday, September 4, 2024 at 4:05 p.m. Eastern time
- Link:
-
Format: Fireside Chat Presentation
- 日期和時間：2024年9月4日，東部時間下午4:05
- 鏈接：
- 形式：爐邊聊天演講
2024 Wells Fargo Healthcare Conference
2024年富國銀行醫療保健會議
- Date and Time: Thursday, September 5, 2024 at 10:15 a.m. Eastern time
- Link:
-
Format: Fireside Chat Presentation
- 日期和時間：2024年9月5日星期四上午10:15，東部時間
- 鏈接：
- 形式：爐邊聊天演講
2024 Cantor Global Healthcare Conference
2024年坎特全球醫療保健會議
- Date and Time: Thursday, September 19, 2024 at 8:35 a.m. Eastern Time
- Link:
-
Format: Fireside Chat Presentation
- 日期和時間：2024年9月19日星期四上午8:35，東部時間
- 鏈接：
- 形式：爐邊聊天演講
For each presentation, an archived replay will be accessible in the Investors section of the Keros website at for up to 90 days following the conclusion of each event.
對於每個演講，每次活動結束後，在Keros網站的投資者部分將提供存檔的重播，最長可達90天。
About Keros Therapeutics, Inc.
關於Keros Therapeutics，Inc.
Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. The Company is a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including blood, bone, skeletal muscle, adipose and heart tissue. By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Keros' lead product candidate, elritercept (KER-050), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis. Keros' second product candidate, cibotercept (KER-012), is being developed for the treatment of pulmonary arterial hypertension for the treatment of cardiovascular disorders. Keros' third product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases.
Keros是一家臨床階段的生物製藥公司，專注於開發和商業化新型治療藥物，用於治療一系列與TGF-ß家族蛋白信號傳導功能紊亂相關的疾病的患者。該公司是了解TGF-ß家族蛋白的作用的領導者，這些蛋白是多種組織的生長、修復和維護的主要調控因子，包括血液、骨骼肌、脂肪和心臟組織。通過利用這種理解，Keros已經發現並正在開發能夠爲患者提供有意義且可能具有疾病修復效果的蛋白治療藥物。Keros的首個產品候選藥物elritercept（KER-050）正在開發用於治療低血細胞計數，包括貧血和血小板減少症的骨髓增生異常綜合徵患者和骨髓纖維化患者。Keros的第二個產品候選藥物cibotercept（KER-012）正在開發用於治療肺動脈高壓症和心血管疾病的患者。Keros的第三個產品候選藥物KER-065正在開發用於治療肥胖症和神經肌肉疾病。
Investor Contact:
Justin Frantz
jfrantz@kerostx.com
617-221-6042
投資者聯繫人：
Justin Frantz
617-221-6042
譯文內容由第三人軟體翻譯。